Kalvista Pharmaceuticals, Inc. · NASDAQ:KALV
Kalvista Pharmaceuticals — Technical Presentation (May 2023)
13 slides from Kalvista Pharmaceuticals's technical presentation, May 2023
Slide 1: HAE Patients’ Decision to Carry On-Demand Treatment When Away from Home
HAE Patients’ Decision to Carry On-Demand Treatment When Away from Home Stephen Betschel,1 Sally van Kooten,2 Markus Heckmann,2 Sherry Danese,3 Ledia Goga,2 Mar Guilarte.4 1Division of Allergy and Immunology, Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, ON Canada;
Slide 2: Disclosures
Disclosures In relation to this presentation, the authors declare the following, real or perceived conflicts of interest: Stephen Betschel – has received speaker/advisor fees and/or research funding from Astria, Canadian Blood Services, CSL Behring, Green Cross, Grifols, Ionis Pharmaceuticals, Kalvi
Slide 3: Background
Background HAE is characterized by recurrent and unpredictable episodes of subcutaneous or submucosal swelling Symptoms of an HAE attack can be painful and debilitating, potentially interfering with the ability to conduct daily activities (work, school, social activities)1 WAO/EAACI 2022 updated gui
Slide 4: Rationale
Rationale This survey investigated the perspectives of people living with HAE regarding their decisions to carry on-demand treatment with them when they leave their homes as part of their daily activities 4 13th C1-Inhibitor Deficiency & Angioedema Workshop, May 4-7, 2023, Budapest, Hungary
Slide 5: Methods
Methods • People living with HAE were recruited by the US Hereditary Angioedema Association (HAEA) to complete an online survey • The survey was self-reported, and took respondents approximately 20 minutes to complete • The survey was completed by 107 individuals between September 6 and October 19,
Slide 6: Respondent Characteristics
Respondent Characteristics A total of 107 respondents completed the survey Total Characteristic (n=107) Age, mean (SD, range) 41yrs (14.6, 16 to 83) Age Category, n(%) 39yrs and younger 56 (52.3%) 40yrs and older 51 (47.7%) Gender, n(%) Female 86 (80.4%) Male 21 (19.6%) Type of Therapy, n(%) On-dema
Slide 7: Respondent Characteristics
Respondent Characteristics Total Treatment (n=107) Current Primary On-demand treatment, n (%) Firazyr/Icatibant 84 (78.5%) Ruconest 13 (12.1%) Berinert 9 (8.4%) Kalbitor 1 (0.9%) Current Prophylactic treatment, n (%) Takhzyro 31 (29.0%) Haegarda 7 (6.5%) Orladeyo 7 (6.5%) Androgens/steroids 5 (4.7%)
Slide 8: Results
Results Proportion of respondents who always carry their HAE on-demand treatment with them when they are away from home, as part of their day-to-day life Total 36% (n=107) On-demand only (n=53) 38% Prophylaxis + on-demand 35% (n=54) 39yrs and younger 29% (n=56) 40yrs and older 45% (n=51) 0% 20% 40%
Slide 9: Results
Results Approximately how long (mean, in hours) respondents will travel away from home without taking on-demand treatment with them Total 3.5 (n=107) On-demand only (n=53) 4.4 Prophylaxis + on-demand 2.5 (n=54) 39yrs and younger 3.1 (n=56) 40yrs and older 4.0 (n=51) 0.0 1.0 2.0 3.0 4.0 5.0 hours 9 1
Slide 10: Results
Results Proportion of respondents who will travel more than 6 hours away from home without taking on-demand treatment with them Total 15% (n=107) On-demand only (n=53) 21% Prophylaxis + on-demand 9% (n=54) 39yrs and younger 13% (n=56) 40yrs and older 18% (n=51) 0% 20% 40% 60% 80% 100% 10 13th C1-Inh
Slide 11: Results
Results Reasons respondents provided for not taking their on-demand treatment with them when they are away from home, as part of their day-to-day life I would rather treat at home 72% I forget to take it with me 56% I am afraid I might leave it somewhere 47% I avoid my triggers 44% I take my prophyl
Slide 12: Conclusions
Conclusions Results highlight that many HAE patients often make the decision to not carry on- demand treatment with them when they are away from home, missing the opportunity to treat attacks early and optimize treatment outcomes Patients will travel for several hours away from home without bringing
Slide 13: Thank you to all survey participants
Thank you to all survey participants, and those who assisted in the development of the survey, and participant recruitment 13th C1-Inhibitor Deficiency & Angioedema Workshop, May 4-7, 2023, Budapest, Hungary
KalVista Pharmaceuticals — Technical Presentation (May 2023) on 6ix